Artificial Intelligence
AI Protein Design & Synthetic Biology
An application of AI foundation models -- protein language models and generative design tools -- to engineer novel proteins, antibodies, and biologics, sitting alongside AI drug discovery as a sibling application of the same techniques applied at the molecular-design level. Beijing/Delaware-based Earendil Labs raised $787 million in March 2026 (backed by Sanofi and a Pfizer/Hillhouse biotech fund) to scale its AI-native biologics platform, which has produced 40+ programs including a Phase 2-ready antibody; Cradle's AI protein engineering platform serves six of the top 25 global pharma companies across 50+ R&D programs; and EvolutionaryScale, founded by former Meta AI researchers, builds ESM3, an open-weight protein language model positioned as a horizontal foundation-model platform for biology.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source · 60% avg. source confidence
- BioSpace / PR Newswire — Earendil Labs raises $787M, Cradle and EvolutionaryScale scale AI protein design60% source confidence
Dependency Map
What AI Protein Design & Synthetic Biology depends on below, and who depends on AI Protein Design & Synthetic Biology above — click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
AI Protein Design & Synthetic Biology's Timeline
A sourced, dated history of AI Protein Design & Synthetic Biology's key moments — founding to present.
Mar 2026 · Earendil Labs raises $787M for AI-driven biologics platform
Earendil Labs raised $787 million in financing, backed by Sanofi and the Pfizer/Hillhouse Biotech Development Fund, to scale its AI-native biologics discovery and development platform, which has already produced more than 40 programs including a Phase 2-ready antibody.